Clinical significance of perineural invasion by prostate cancer

Published Date: 08 Mar 2023

This study examines the clinical impact of unilateral perineural invasion in prostate cancer. How does unilaterality affect long-term oncology outcomes?

Read Full News

Latest News

Optimizing DPYD Testing Prior to Fluoropyrimidine Therapy

A PDSA-driven QI project cut DPYD testing turnaround from 16.7 to 12.7 days, though "expedite" order comments alone showed little added benefit.

Syngeneic Modeling of Diet-Driven Liver Cancer

New mouse model of MASLD-driven liver cancer shows sex-based tumor onset and responds to FOG-001, a first-in-class Wnt/β-catenin inhibitor.

VA Dashboards for Clinical Pathway & Genetic Testing Use

New VA dashboards tracking Clinical Pathway adherence helped raise lung cancer testing documentation from 57% to 76% and treatment templates to 42%.

Melanoma Clinical Pearls: 5 Core Principles

Are you up to date on excision margins, sentinel node candidacy, and hereditary risk? Review five critical clinical nuances to refine your approach to melanoma care.

Q&A: Melanoma Clinical Guidance

Do you know the current guidelines for suspicious lesion workups, pathology drivers, and targeted imaging? Explore key diagnostic and management questions shaping modern melanoma care.

Woman’s 3-Year Lip Swelling Reveals Granulomatous Cheilitis

A chronic, painless lip swelling proved diagnostically challenging until histology showed epithelioid granulomas and excluded infection and sarcoidosis.

Todays Updates

Baseline RV Dysfunction May predict Sotatercept response in PAH

Baseline RV Dysfunction May predict Sotatercept response in PAH

FDA Grants Priority Review to Huntington Disease Gene Therapy BLA Marco Meglio

The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.

On Beyond Seizures: Unmet Needs in Pediatric Epilepsy Clinics Susan Duberstein, MD

Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.

Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development Marco Meglio

Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.

AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS Marco Meglio

AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.

Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study Louie Pasculli

Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease Isabella Ciccone, MPH, Cindy Zadikoff, MD, MSc

The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.

Todays Updates

Baseline RV Dysfunction May predict Sotatercept response in PAH

Baseline RV Dysfunction May predict Sotatercept response in PAH

FDA Grants Priority Review to Huntington Disease Gene Therapy BLA Marco Meglio

The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.

On Beyond Seizures: Unmet Needs in Pediatric Epilepsy Clinics Susan Duberstein, MD

Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.

Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development Marco Meglio

Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.

AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS Marco Meglio

AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.

Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study Louie Pasculli

Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease Isabella Ciccone, MPH, Cindy Zadikoff, MD, MSc

The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.

Latest News

A PDSA-driven QI project cut DPYD testing turnaround from 16.7 to 12.7 days, though "expedite" order comments alone showed little added benefit.

New mouse model of MASLD-driven liver cancer shows sex-based tumor onset and responds to FOG-001, a first-in-class Wnt/β-catenin inhibitor.

New VA dashboards tracking Clinical Pathway adherence helped raise lung cancer testing documentation from 57% to 76% and treatment templates to 42%.

Are you up to date on excision margins, sentinel node candidacy, and hereditary risk? Review five critical clinical nuances to refine your approach to melanoma care.

Do you know the current guidelines for suspicious lesion workups, pathology drivers, and targeted imaging? Explore key diagnostic and management questions shaping modern melanoma care.

A chronic, painless lip swelling proved diagnostically challenging until histology showed epithelioid granulomas and excluded infection and sarcoidosis.

News All Time

A Woman on Ruxolitinib Had TB That Mimicked Metastases

A woman receiving ruxolitinib for polycythemia vera developed disseminated tuberculosis despite a negative IGRA, highlighting the limits of screening.

Pediatric Gastroenterology Faces AI Reality Check

From nutrition screening to IBD monitoring, AI shows promise in pediatric gastroenterology — yet experts stress pediatric validation is essential.

Hidradenitis Suppurativa–Associated Squamous Cell Carcinoma

Four cases highlight the aggressive nature of cutaneous squamous cell carcinoma arising in chronic perianal and gluteal hidradenitis suppurativa.

FDA Neurology Digest: August 2026

A monthly snapshot of FDA activity involving therapies used in the prevention, diagnosis, and treatment of neurologic conditions.

Sentinel Lymph Node Biopsy De-Implementation in Women Veterans

This study sought to quantify low-value sentinel lymph node biopsy practices among populations eligible for a de-escalated surgical approach in VA.

Expanding Access to Pediatric Dermatology Through Store-and-Forward Teledermatology

A pediatric dermatology–specific store-and-forward service can enhance access to specialty expertise, support care coordination, and integrate into clinical practice without increasing consultant workload.

Informed-Consent Gaps in Prostate Cancer Genetic Testing

Are oncologists missing key details during genetic testing consent? Dr Maurie Markman reviews new data and why current informed consent falls short.

Kratom: An Emerging Cause of Drug-Induced Hyperpigmentation

Kratom is an increasingly common environmental exposure with potential dermatologic consequences. Learn to recognize its association with hyperpigmentation.

Rethinking Laboratory Screening for Patients Receiving Biologics

Do all patients on biologics need routine laboratory screening? A risk-based approach can help clinicians determine when testing is truly worthwhile.

CCND1-Negative Mantle Cell Lymphoma With Balanced CCND3-IGH Rearrangement: Case Report and Literature Review

CCND1-Negative Mantle Cell Lymphoma With Balanced CCND3-IGH Rearrangement: Case Report and Literature Review

Development of a National Hematology Program: Advancing Classical Hematology Care for Veterans

Many classical (nonmalignant) hematologic disorders—including venous thromboembolism (VTE), sickle cell trait, bleeding or clotting disorders, G6PD deficiency, and others—have a propensity to manifest under physical stress or trauma.

Solitary Tender Nodule on the Forearm

A 36-year-old woman presented to the dermatology department with a nodule on the left forearm. What’s your diagnosis?

S1 Episode 4: How Early Is Early Enough to Reverse MASLD?

Drs VanWagner and Chen discuss whether fatty liver is reversible, weight-loss targets, diet quality, exercise, and where GLP-1s and bariatric surgery fit into MASLD treatment.

Teen With a Slowly Enlarging Annular Hyperkeratotic Papule

The lesion initially appeared as a small papule and gradually enlarged, with more noticeable growth in recent months. The lesion was not painful, pruritic, or bleeding.

ArteraAI: Current Indications in Prostate Cancer

From localized disease to recurrence, where can ArteraAI add actionable insight for patients with prostate cancer?

Thyroid Surgery: Practical Strategies for Optimal Post-op Care

Drs Kaniksha Desai and Michael Yeh discuss practical aspects of postoperative thyroid surgery care.

Recommended News For You

In cancer patients taking immune checkpoint inhibitors, systematic vitamin D supplementation improves outcomes.

In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.

Cancer Patients Are Receiving More and More Stupid Immunotherapy.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

Researchers investigate risk of developing multiple primary cancers after surviving bowel cancer

Recommended Articles For You

Modern Perspectives in Hematology for Modern Medicine 

Protein Degradation in Cancer: PROTACs and Targeted Degraders for Previously Difficult-to-Drug Targets 

The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring 

AI in Genomics: Decoding the Human Genome for Cancer Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adopted cancer cells and the effects of their presence.

2.

Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial

3.

Products for Intimate Care and Cancer; Boost for Colorectal Cancer Stool Tests; Ultrasonic Biopsy?

4.

La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.

5.

The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.

1.

Clinical Perspectives in Oncology for Better Care

2.

What are Acanthocytes? Understanding the Role of Spiky Red Blood Cells

3.

All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment

4.

Finding Support: Connecting with the Vitiligo Community

5.

Understanding Hidrocystoma: Symptoms, Causes, and Treatment Options 

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II

2.

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

5.

Navigating the Complexities of Ph Negative ALL - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot